Search Results
STOP PEDS RCT (Streamlined Treatment of Pulmonary Exacerbations in Pediatrics Randomized Controlled Trial) (STOP PEDS RCT)
In this study, we are going to compare two ways of treating mild respiratory illnesses in children with Cystic Fibrosis (CF). One is immediate antibiotics (increase airway clearance and start oral antibiotics right away) and the other is tailored therapy (increase airway clearance right away but only start oral antibiotics if symptoms worsen or do not improve). We are looking at how safe each option is and how well each one works. To do this, we will randomize participants (like flipping a coin) to one of these two approaches if a mild respiratory illness happens over the next 12 months.
• Age: for main study group and non-HEMT group: age 6 to less than 19 years old OR for preschool group: age 3 to less than 6 years old
• diagnosis of Cystic Fibrosis (CF)
• for main study group and non-highly effective modulator therapy (HEMT) group, able to do spirometry
• able to receive text messages and access the internet
• see link to clincialtrials.gov for complete inclusion criteria
• history of solid organ transplant
• positive culture for Mycobacterium abscessus in the prior 12 months
• three or more IV antibiotic-treated pulmonary exacerbations (PEx) in the prior 12 months
• treatment with chronic oral antibiotics other than azithromycin at enrollment
• see link to clinicaltrials.gov for complete exclusion criteria
MN CF Center Consent (PortCF) Cystic Fibrosis (CF) Center Program Accreditation and Funding
This retrospective, longitudinal project is to collect certain demographic and clinical health status information for entry into the CF Foundation Patient Registry (also known as PortCF). The registry has played an important role in CF research and will continue to do so. In addition, much of the same information is entered into the University of Minnesota Cystic Fibrosis Center Research Database. This patient database has been maintained since 1975.
• possible diagnosis of Cystic Fibrosis (CF) or CF-related complications
• receive care at the MN CF Center
ABATE-IP-18: A Phase 1b, Multi-center Study of IV Gallium Nitrate in Patients with Cystic Fibrosis who are Colonized with Nontuberculous Mycobacteria (The ABATE Study) (ABATE)
The purpose of this research study is to test the safety of giving two separate 5-day infusions (starting on Day 1 and again around Day 15) through a vein with a drug called gallium nitrate. Laboratory tests suggest that this drug may be able to fight Nontuberculous Mycobacteria (NTM) infections
• diagnosis of cystic fibrosis
• persistent Nontuberculous Mycobacterium lung infection (NTM)
• able to expectorate sputum
• enrolled in the CFF Patient Registry
• see link to clinicaltrials.gov for complete inclusion & exclusion criteria
• history of solid organ or hematological transplantation
• current diagnosis of osteoporosis
• women who are pregnant or breast feeding
• men and women who are unwilling to practice a medically acceptable form of contraception
SENDCF-OB-25: Study to Enable New Diagnostics for Pulmonary Microbes in People with CF
The purpose of this study is to evaluate new ways to identify lung infections in people with cystic fibrosis (CF). Researchers will use the information to better understand lung health and help improve future testing methods for people with CF.
• ages 16 and older
• diagnosis of Cystic Fibrosis (CF)
CVD in Women with CF: Assessing Cardiovascular Risk in Menopausal Women with Cystic Fibrosis
Women with cystic fibrosis (CF) during peri- and postmenopausal stages may be at increased risk for cardiovascular disease, partly mediated by accelerated cardiometabolic risks. This cross-sectional study aims to address critical gaps in understanding cardiovascular disease (CVD) risk in women with CF and will inform early interventions tailored to this growing population.
• women ages 45 years and older
• diagnosed with cystic fibrosis
• pregnant or suspect you may be pregnant
• cognitive or memory difficulties
• unable to read or speak English
HM2024-28: A Pilot Study to Investigate the Clinical Utility of Tremoflo Airway Oscillometry in the Pediatric and Adolescent Population with Pulmonary Pathology or at Risk of Lung Injury
The purpose of this study is to help investigators learn more about what are the best methods for diagnosing and monitoring lung problems.
• age 0 to 24
• physician thinks patient might benefit from early and more frequent pulmonary function monitoring
• at risk for developing lung disease
• unlikely to complete required study components